EP 1817281 A1 20070815 - N- [(3S)- PYRROLIDIN-3-YL]- BENZAMIDE DERIVATIVES AS MONOAMINE RE-UPTAKE INHIBITORS

Title (en)

N- [(3S)- PYRROLIDIN-3-YL]- BENZAMIDE DERIVATIVES AS MONOAMINE RE-UPTAKE INHIBITORS

Title (de)

N- [(3S)-PYRROLIDIN-3-YL]- BENZAMIDDERIVATE ALS MONOAMINWIEDERAUFNAHMEHEMMER

Title (fr)

DERIVES DE N-[(3S)-PYRROLIDIN-3-YL]-BENZAMIDE UTILES COMME INHIBITEURS DE RECAPTAGE DE MONOAMINE

Publication

EP 1817281 A1 20070815 (EN)

Application

EP 05808510 A 20051118

Priority

IB 2005003643 W 20051118
GB 0425766 A 20041123

Abstract (en)

[origin: WO2006056884A1] A compound of Formula (I) and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R1, R2, R3 and R20 are each independently H, CI, Br, F, I, CF3, OCF3, Me or Et; R4 is het or C3-7 cycloalkyl optionally substituted by C1-4 alkyl, C1-4 alkoxy, alkoxyalkyl containing 2 to 4 carbon atoms or -S-(C1-4 alkyl); a is 0 or 1; and het is a non-aromatic 4-, 5- or 6- membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6- membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom, wherein the het group is optionally substituted by at least one substituent independently selected from C1-8alkyl, C1-8alkoxy, OH, halo, CF3, OCF3, SCF3, hydroxy-C1-6alkyl, C1-4 alkoxy-C1-6alkyl and C1-4 alkyl-S-C1-4alkyl; provided that at least one of R1, R2 and R3 are other than H. The compounds of the invention exhibit activity as both serotonin and noradrenaline re-uptake inhibitors and therefore have utility in a variety of therapeutic areas, for example urinary incontinence.

IPC 8 full level

C07D 207/14 (2006.01); A61K 31/40 (2006.01); C07D 405/12 (2006.01)

CPC (source: EP KR)

A61K 31/40 (2013.01 - KR); A61P 13/00 (2017.12 - EP); A61P 13/02 (2017.12 - EP); A61P 13/10 (2017.12 - EP); A61P 15/00 (2017.12 - EP); A61P 15/10 (2017.12 - EP); A61P 15/12 (2017.12 - EP); A61P 21/00 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/04 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 207/14 (2013.01 - EP); C07D 207/16 (2013.01 - KR); C07D 405/12 (2013.01 - EP)

Citation (search report)

See references of WO 2006056884A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK YU

DOCDB simple family (publication)

WO 2006056884 A1 20060601; AP 2007004003 A0 20070630; AR 052243 A1 20070307; AU 2005308534 A1 20060601; BR PI0518486 A2 20081118; CA 2589258 A1 20060601; CN 101065355 A 20071031; CR 9171 A 20070704; EA 011217 B1 20090227; EA 200700920 A1 20071228; EP 1817281 A1 20070815; GB 0425766 D0 20041222; GT 200500337 A 20060613; IL 183191 A0 20070819; JP 2008520646 A 20080619; JP 4233596 B2 20090304; KR 100886294 B1 20090304; KR 20070086599 A 20070827; MA 29038 B1 20071101; MX 2007006138 A 20070719; NL 1030485 A1 20060524; NL 1030485 C2 20061107; NL 1032760 A1 20061213; NL 1032760 C2 20070417; NO 20072486 L 20070620; PA 8653501 A1 20060602; PE 20061056 A1 20061108; SV 2006002311 A 20060914; TN SN07201 A1 20081121; TW 200626543 A 20060801; TW I300776 B 20080911; UY 29224 A1 20060630; ZA 200703910 B 20080925

DOCDB simple family (application)

IB 2005003643 W 20051118; AP 2007004003 A 20051118; AR P050104866 A 20051121; AU 2005308534 A 20051118; BR PI0518486 A 20051118; CA 2589258 A 20051118; CN 200580040102 A 20051118; CR 9171 A 20070607; EA 200700920 A 20051118; EP 05808510 A 20051118; GB 0425766 A 20041123; GT 200500337 A 20051122; IL 18319107 A 20070514; JP 2007542360 A 20051118; KR 20077014351 A 20070622; MA 29935 A 20070523; MX 2007006138 A 20051118; NL 1030485 A 20051122; NL 1032760 A 20061027; NO 20072486 A 20070515; PA 8653501 A 20051123; PE 2005001362 A 20051121; SV 2005002311 A 20051123; TN SN07201 A 20070522; TW 94140922 A 20051122; UY 29224 A 20051122; ZA 200703910 A 20070515